The raubasine market is expected to grow at a significant CAGR during the forecast period (2021-2027). Raubasine (ajmalicine), a Rauwolfia alkaloid, has been discovered to have a wide range of applications in the treatment of circulatory disorders, particularly in the alleviation of blockage of normal cerebral blood flow. It has been used to treat high blood pressure when combined with other Rauwolfia alkaloids. Raubasine is an antihypertensive medication used to treat hypertension. Card-Lamuran, Circolene, Cristanyl, Duxil, Duxor, Hydroxysarpon, Iskedyl, Isosarpan, Isquebral, Lamuran, Melanex, Saltucin Co, Salvalion, and Sarpan are some of the brand names used. Raubasine is an antagonist for the alpha 1-adrenergic receptor.

Blood pressure is defined as the pressure exerted on the artery walls by the blood during the transportation of blood from the heart to the rest of the body. Hypertension is a commonly known condition of high blood pressure which may cause harm to the heart and also cause other health concerns. Hypertension was the major cause for half of the fatalities in the US in 2019 as per records stated by the CDC. Almost half of the population (47%) in the US are said to be suffering from hypertension and are on medication. Only roughly 1/4th of individuals with hypertension (24 %) have their condition under control. 

Blood pressure of 140/90 mmHg or greater is found in around half of the people (45%) with uncontrolled hypertension. This comprises 37 million adults in the US. Approximately 34 million individuals who have been advised to take medicine may require a prescription. A blood pressure of 140/90 mmHg or above affects about two-thirds of this population (19 million). In the US in 2019, high blood pressure was a main or contributing cause of death for 516,955 persons. Therefore, the rising prevalence of hypertension is expected to drive the market for Raubasine globally.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Type 

o By Application 

• Regions Covered

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Indo Phytochem Pharmaceuticals, Johnson & Johnson Ltd., Merck & Co., Novartis AG, Pfizer, Inc., Quad Life Sciences Private Limited, 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Raubasine Market by Segments

By Type

• Injectable
• Tablets

By Application

• Anti-Hypertension

Global Raubasine Market by Region